[Source: Globe Newswire] – Caris Life Sciences, Inc., a leading biosciences company focused on enabling precise and personalized healthcare through the highest quality anatomic pathology, molecular profiling, and blood-based diagnostic services, announced today recent appointments and additions to its senior scientific staff at facilities in Lausanne, Switzerland and Phoenix, Arizona to focus on novel biosignature identification and next-generation diagnostic assay development. The expansion includes 20 research scientists, technologists, and bioinformaticians. Caris Life Sciences has a long-standing and increasing commitment to commercialization of cutting-edge biomedical science, as evidenced most recently by its Carisome™ circulating microvesicle (cMV) technology. This proprietary blood-based technology is currently being developed for earlier, more accurate and less invasive testing for cancer and other complex diseases.
For more information: Caris Life Sciences Expands Molecular R&D Capabilities Globally to Speed Commercialization Efforts